World Health Organisation (WHO) declared on Friday that the popular anti-viral drug remdesivir should not be used for the treatment of hospitalised COVID-19 patients, maintaining that clinical trials had failed to prove it efficacy.
Janet Diaz, WHO chief clinician in a press briefing at WHO headquarters Geneva, Switzerland made it known that there was no clear prove that the use of remdesivir helps in reducing the risk of death or gives oxygen support to patients with COVID-19.
The WHO in the middle of October published preliminary clinical trial results that showed that the drug is less effective.
On the contrary, the U.S. Food and Drug Administration previously approved remdesivir, a drug made by U.S. company Gilead Sciences, in October, 2020.
Similarly, the drug was also endorsed by European Union for treating severe cases of the disease caused by coronavirus.